The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
A melanocyte lineage program confers resistance to MAP kinase pathway inhibition
Open accessAbstract
Malignant melanomas harbouring point mutations (Val600Glu) in the serine/threonine-protein kinase BRAF (BRAF(V600E)) depend on RAF-MEK-ERK signalling for tumour cell growth. RAF and MEK inhibitors show remarkable clinical efficacy in BRAF(V600E) melanoma; however, resistance to these agents remains a formidable challenge. Global characterization of resistance mechanisms may inform the development of more effective therapeutic combinations. Here we carried out systematic gain-of-function resistance studies by expressing more than 15,500 genes individually in a BRAF(V600E) melanoma cell line treated with RAF, MEK, ERK or combined RAF-MEK inhibitors. These studies revealed a cyclic-AMP-dependent melanocytic signalling network not previously associated with drug resistance, including G-protein-coupled receptors, adenyl cyclase, protein kinase A and cAMP response element binding protein (CREB). Preliminary analysis of biopsies from BRAF(V600E) melanoma patients revealed that phosphorylated (active) CREB was suppressed by RAF-MEK inhibition but restored in relapsing tumours. Expression of transcription factors activated downstream of MAP kinase and cAMP pathways also conferred resistance, including c-FOS, NR4A1, NR4A2 and MITF. Combined treatment with MAPK-pathway and histone-deacetylase inhibitors suppressed MITF expression and cAMP-mediated resistance. Collectively, these data suggest that oncogenic dysregulation of a melanocyte lineage dependency can cause resistance to RAF-MEK-ERK inhibition, which may be overcome by combining signalling- and chromatin-directed therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Notably, sgRNAs targeting ETS2 were significantly depleted, consistent with a previous finding of its emergence as a resistance hit through a gain-of-function screen for resistance to MAPK pathway inhibitors in BRAF V600E melanoma.49”
From Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer (2026) · cites this paper as [49]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Consistent with this, analysis of primary CRC samples from previously published cohorts49 revealed strong positive correlations between SMAD1 expression, FGFR1 and FGFR3 signaling activity, and Paneth cell signatures (Figures S6A and S6B).”
From Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer (2026) · cites this paper as [49]
Experimental — accuracy not yet measuredIn the citing paper
“In melanoma, core regulators of neural crest lineage, MITF and SOX10, regulate the emergence of distinct cell states associated with drug tolerance establishment after treatment [61,82,83,84].”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [82]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationCombined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Self-citationPierce, K. L., Premont, R. T., & Lefkowitz, R. J. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm908 · Cited by 2,712
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,205
Self-citationGarraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., et al. (2005) · Nature · doi:10.1038/nature03664 · Cited by 1,548
Self-citationCOT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
Self-citationImproved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-63198 · Cited by 1,330
Self-citationBRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G. A., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2005) · Nature · doi:10.1038/nature04304 · Cited by 1,326
Self-citationRaf-1 activates MAP kinase-kinase
Kyriakis, J. M., App, H., Zhang, X., Banerjee, P. T., Brautigan, D. L., Rapp, U. R., & Avruch, J. (1992) · Nature · doi:10.1038/358417a0 · Cited by 1,263
Hodgkinson, C. A., Moore, K. J., Nakayama, A., Steingrı́msson, E., Copeland, N. G., Jenkins, N. A., & Arnheiter, H. (1993) · Cell · doi:10.1016/0092-8674(93)90429-t · Cited by 1,092
Cited by
Sorted by citations
Items 101–200 of 446
Pro-Survival Role of MITF in Melanoma
Hartman, M. L., & Czyż, M. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.319 · Cited by 96
Melanoblast transcriptome analysis reveals pathways promoting melanoma metastasis
Marie, K. L., Sassano, A., Yang, H. H., Michalowski, A. M., Michael, H. T., Guo, T. W., Tsai, Y. C., Weissman, A. M., Lee, M. P., Jenkins, L. M. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14085-2 · Cited by 90
The Hippo pathway oncoprotein YAP promotes melanoma cell invasion and spontaneous metastasis
Zhang, X., Yang, L., Szeto, P., Abali, G. K., Zhang, Y., Kulkarni, A., Amarasinghe, K. C., Li, J., Vergara, I. A., Molania, R., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1362-9 · Cited by 92
Feigin, M. E., Xue, B., Hammell, M., & Muthuswamy, S. K. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320239111 · Cited by 85
MITF Modulates Therapeutic Resistance through EGFR Signaling
Ji, Z., Chen, Y. E., Kumar, R., Taylor, M., Njauw, C.-N. J., Miao, B., Frederick, D. T., Wargo, J. A., Flaherty, K. T., Jonsson, G. G., et al. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.105 · Cited by 87
Self-citationFunctional annotation of rare gene aberration drivers of pancreatic cancer
Tsang, Y. H., Dogruluk, T., Tedeschi, P. M., Wardwell‐Ozgo, J., Lu, H., Espitia, M., Nair, N. V., Minelli, R., Chong, Z., Chen, F., et al. (2016) · Nature Communications · doi:10.1038/ncomms10500 · Cited by 84
MAPK kinase signalling dynamics regulate cell fate decisions and drug resistance
Rauch, N., Rukhlenko, O. S., Kölch, W., & Kholodenko, B. Ν. (2016) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2016.07.019 · Cited by 86
A slow-cycling subpopulation of melanoma cells with highly invasive properties
Perego, M., Maurer, M., Wang, J., Shaffer, S. M., Müller, A. C., Parapatics, K., Li, L., Hristova, D. M., Shin, S. A., Keeney, F., et al. (2017) · Oncogene · doi:10.1038/onc.2017.341 · Cited by 86
Adaptive redox homeostasis in cutaneous melanoma
Arslanbaeva, L. R., & Santoro, M. M. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101753 · Cited by 87
BRAF/MAPK and GSK3 signaling converges to control MITF nuclear export
Ngeow, K. C., Friedrichsen, H. J., Li, L., Zeng, Z., Andrews, S., Volpon, L., Brunsdon, H., Berridge, G., Picaud, S., Fischer, R., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1810498115 · Cited by 89
Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review
Tangella, L. P., Clark, M. E., & Gray, E. S. (2020) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2020.129736 · Cited by 92
Fan, F., Bashari, M. H., Morelli, E., Tonon, G., Malvestiti, S., Vallet, S., Jarahian, M., Seckinger, A., Hose, D., Bakiri, L., et al. (2016) · Leukemia · doi:10.1038/leu.2016.358 · Cited by 82
Liu, X., Si, W., Liu, X., He, L., Ren, J., Yang, Z., Yang, J., Li, W., Liu, S., Pei, F., et al. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0744-2 · Cited by 80
B-Raf Inhibition in the Clinic: Present and Future
Fiskus, W. C., & Mitsiades, N. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-090514-030732 · Cited by 79
Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers
Untch, B. R., Anjos, V. D., García-Rendueles, M. E. R., Knauf, J. A., Krishnamoorthy, G. P., Saqcena, M., Bhanot, U. K., Socci, N. D., Ho, A. L., Ghossein, R. A., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1925 · Cited by 78
Critical parameters in targeted drug development: the pharmacological audit trail
Banerji, U., & Workman, P. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.06.001 · Cited by 78
The Hippo Pathway as a Driver of Select Human Cancers
Kulkarni, A., Chang, M. T., Vissers, J. H. A., Dey, A., & Harvey, K. F. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.04.004 · Cited by 77
MITF controls the TCA cycle to modulate the melanoma hypoxia response
Louphrasitthiphol, P., Ledaki, I., Chauhan, J. S., Falletta, P., Siddaway, R., Buffa, F. M., Mole, D. R., Soga, T., & Goding, C. R. (2019) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12802 · Cited by 82
Inflammation-Induced Plasticity in Melanoma Therapy and Metastasis
Hölzel, M., & Tüting, T. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.03.009 · Cited by 80
Vitiello, M., Tuccoli, A., D’Aurizio, R., Sarti, S., Giannecchini, L., Lubrano, S., Marranci, A., Evangelista, M., Peppicelli, S., Ippolito, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15915 · Cited by 73
Self-citationRamms, D. J., Raimondi, F., Arang, N., Herberg, F. W., Taylor, S. S., & Gutkind, J. S. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000269 · Cited by 73
Leitão, S. M., Drake, B., Pinjušić, K., Pierrat, X., Navikas, V., Nievergelt, A. P., Brillard, C., Djekic, D., Rađenović, A., Persat, A., et al. (2021) · ACS Nano · doi:10.1021/acsnano.1c05202 · Cited by 70
The Slow Cycling Phenotype: A Growing Problem for Treatment Resistance in Melanoma
Ahn, A., Chatterjee, A., & Eccles, M. R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0535 · Cited by 75
The combination of checkpoint immunotherapy and targeted therapy in cancer
Karachaliou, N., Gonzalez-Cao, M., Sosa, A. E., Berenguer, J., Bracht, J. W. P., Ito, M., & Rosell, R. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.06.47 · Cited by 71
Using Big Data to Discover Diagnostics and Therapeutics for Gastrointestinal and Liver Diseases
Wooden, B., Goossens, N., Hoshida, Y., & Friedman, S. L. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.09.065 · Cited by 69
JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma
Titz, B., Lomova, A., Le, A., Hugo, W., Kong, X., ten Hoeve, J., Friedman, M., Shi, H., Moriceau, G., Song, C., et al. (2016) · Cell Discovery · doi:10.1038/celldisc.2016.28 · Cited by 75
Targeted Therapy Resistance Mechanisms and Therapeutic Implications in Melanoma
Chen, G., & Davies, M. A. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2014.03.001 · Cited by 66
Ma, M., Dai, J., Tang, H., Xu, T., Yu, S., Si, L., Cui, C., Sheng, X., Chi, Z., Mao, L., et al. (2019) · Theranostics · doi:10.7150/thno.30516 · Cited by 67
Current State of Melanoma Therapy and Next Steps: Battling Therapeutic Resistance
Fateeva, A., Eddy, K., & Chen, S. (2024) · Cancers · doi:10.3390/cancers16081571 · Cited by 67
SOX10 Regulates Melanoma Immunogenicity through an IRF4–IRF1 Axis
Yokoyama, S., Takahashi, A., Kikuchi, R., Nishibu, S., Lo, J. A., Hejna, M., Moon, W. M., Kato, S., Zhou, Y., Hodi, F. S., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-2078 · Cited by 63
Gallagher, S. J., Mijatov, B., Gunatilake, D., Tiffen, J. C., Gowrishankar, K., Jin, L., Pupo, G. M., Cullinane, C. M., Prinjha, R. K., Smithers, N. N., et al. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.243 · Cited by 62
STAT3 promotes melanoma metastasis by CEBP-induced repression of the MITF pathway
Swoboda, A., Soukup, R., Eckel, O., Kinslechner, K., Wingelhofer, B., Schörghofer, D., Sternberg, C., Pham, H. T. T., Vallianou, M., Horvath, J., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01584-6 · Cited by 63
Hu, Y., Huang, J., Li, Y., Jiang, L., Ouyang, Y., Li, Y., Yang, L., Zhao, X., Huang, L., Xiang, H., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15038 · Cited by 61
Massively parallel high-order combinatorial genetics in human cells
Wong, A. S. L., Choi, G. C. G., Cheng, A. A., Purcell, O., & Lu, T. K. (2015) · Nature Biotechnology · doi:10.1038/nbt.3326 · Cited by 60
Ballotti, R., Chéli, Y., & Bertolotto, C. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01290-7 · Cited by 63
Vanneste, M., Feddersen, C. R., Varzavand, A., Zhu, E. Y., Foley, T. M., Zhao, L. Q., Holt, K. H., Milhem, M. M., Piper, R. C., Stipp, C. S., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00442 · Cited by 58
Najem, A., Krayem, M., Salès, F., Hussein, N., Badran, B. M., Robert, C., Awada, A. H., Journé, F., & Ghanem, G. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.033 · Cited by 57
Massi, D., Mihic‐Probst, D., Schadendorf, D., Dummer, R., & Mandalà, M. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102060 · Cited by 56
Keller, H. R., Zhang, X., Li, L., Schaider, H., & Wells, J. W. (2017) · Oncotarget · doi:10.18632/oncotarget.18523 · Cited by 55
Jiang, P., Lee, W., Li, X., Johnson, C., Liu, J. S., Brown, M. A., Aster, J. C., & Liu, X. S. (2018) · Cell Systems · doi:10.1016/j.cels.2018.01.009 · Cited by 55
Wang, V. E. H., Xue, J. Y., Frederick, D. T., Cao, Y., Lin, E., Wilson, C., Urisman, A., Carbone, D. P., Flaherty, K. T., Bernards, R., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2779 · Cited by 57
Self-citationSmalley, I., Law, V., Wyatt, C. J., Evernden, B. R., Fang, B., Koomen, J. M., Welsh, E. A., Macaulay, R. J. B., Forsyth, P. A., & Smalley, K. S. M. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2840 · Cited by 55
Gallagher, S. J., Gunatilake, D., Beaumont, K. A., Sharp, D. M., Tiffen, J. C., Heinemann, A., Weninger, W., Haass, N. K., Wilmott, J. S., Madore, J., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.31199 · Cited by 56
Babapoor, S., Fleming, E. S., Wu, R., & Dadras, S. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107502 · Cited by 53
MITF Expression Predicts Therapeutic Vulnerability to p300 Inhibition in Human Melanoma
Kim, E. J., Zucconi, B. E., Wu, M., Nocco, S. E., Meyers, D. J., McGee, J. S., Venkatesh, S., Cohen, D. L., Gonzalez, E. C., Ryu, B., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2331 · Cited by 54
Lineage Plasticity: The New Cancer Hallmark on the Block
Mehta, A., & Stanger, B. Z. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-1067 · Cited by 54
AP-1 transcription factor network explains diverse patterns of cellular plasticity in melanoma cells
Comandante-Lou, N., Baumann, D. G., & Fallahi‐Sichani, M. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111147 · Cited by 55
MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB
Rose, A. A. N., Annis, M. G., Frederick, D. T., Biondini, M., Dong, Z., Kwong, L. N., Chin, L., Keler, T., Hawthorne, T. R., Watson, I. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1192 · Cited by 53
Self-citationCOP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors
Xie, Y., Cao, Z., Wong, E. W. P., Guan, Y., Ma, W., Zhang, J. Q., Walczak, E. G., Murphy, D. A., Ran, L., Sirota, I., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci94840 · Cited by 51
Lun, X., Szklarczyk, D., Gábor, A., Dobberstein, N., Zanotelli, V. R., Sáez-Rodríguez, J., von Mering, C., & Bodenmiller, B. (2018) · Molecular Cell · doi:10.1016/j.molcel.2019.04.021 · Cited by 54
Current understanding of epigenetics role in melanoma treatment and resistance
Fath, M. K., Azargoonjahromi, A., Soofi, A., Almasi, F., Hosseinzadeh, S., Khalili, S., Sheikhi, K., Ferdousmakan, S., Owrangi, S., Fahimi, M., et al. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02738-0 · Cited by 51
A phase I trial of panobinostat ( LBH 589) in patients with metastatic melanoma
Ibrahim, N., Buchbinder, E. I., Granter, S. R., Rodig, S. J., Giobbie‐Hurder, A., Becerra, C., Tsiaras, A., Gjini, E., Fisher, D. E., & Hodi, F. S. (2016) · Cancer Medicine · doi:10.1002/cam4.862 · Cited by 49
The CREB coactivator CRTC2 promotes oncogenesis in LKB1-mutant non–small cell lung cancer
Rodón, L., Svensson, R. U., Wiater, E., Chun, M. G. H., Tsai, W., Eichner, L. J., Shaw, R. J., & Montminy, M. (2019) · Science Advances · doi:10.1126/sciadv.aaw6455 · Cited by 50
Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy
Gallagher, S. J., Tiffen, J. C., & Hersey, P. (2015) · Cancers · doi:10.3390/cancers7040870 · Cited by 49
Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma
Brummer, C., Färber, S., Bruß, C., Blank, C. U., Lacroix, R., Haferkamp, S., Herr, W., Kreutz, M. P., & Renner, K. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.11.018 · Cited by 48
A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma
Hayes, T. K., Luo, F., Cohen, O., Goodale, A. B., Lee, Y., Pantel, S., Bagul, M., Piccioni, F., Root, D. E., Garraway, L. A., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2711 · Cited by 48
Self-citationOrtiz‐Cuaran, S., Mezquita, L., Swalduz, A., Aldea, M. D., Mazières, J., Léonce, C., Jovelet, C., Pradines, A., Avrillon, V., Flores, W. R. C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1037 · Cited by 49
Steroid hormone influence on melanomagenesis
Mitkov, M. V., Joseph, R. W., & Copland, J. A. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.09.020 · Cited by 47
Friedman, A. A., Amzallag, A., Pruteanu-Malinici, I., Baniya, S., Cooper, Z. A., Piris, A., Hargreaves, L., Igras, V., Frederick, D. T., Lawrence, D. P., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140310 · Cited by 47
Self-citationSignaling and Immune Regulation in Melanoma Development and Responses to Therapy
Lin, W. M., & Fisher, D. E. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100208 · Cited by 47
Leclerc, J., Garandeau, D., Pandiani, C., Gaudel, C., Bille, K., Nottet, N., Garcia, V., Colosetti, P., Pagnotta, S., Bahadoran, P., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0500-0 · Cited by 53
Cyclic adenosine monophosphate (cAMP) signaling in melanocyte pigmentation and melanomagenesis
Bang, J., & Zippin, J. H. (2020) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12920 · Cited by 48
Wessely, A., Steeb, T., Berking, C., & Heppt, M. V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115761 · Cited by 49
Integrated molecular drivers coordinate biological and clinical states in melanoma
Conway, J. R., Dietlein, F., Taylor-Weiner, A. N., AlDubayan, S. H., Vokes, N. I., Keenan, T. E., Reardon, B. M., He, M. X., Margolis, C. A., Weirather, J. L., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-00739-1 · Cited by 44
Borre, P. V., Gunda, V., McFadden, D. G., Sadow, P. M., Varmeh, S., Bernasconi, M. J., & Parangi, S. (2014) · Oncotarget · doi:10.18632/oncotarget.2130 · Cited by 43
Jiang, M. (2016) · Tumor Biology · doi:10.1007/s13277-016-5301-x · Cited by 43
Smith, M. P., Rana, S., Ferguson, J., Rowling, E. J., Flaherty, K. T., Wargo, J. A., Marais, R., & Wellbrock, C. (2018) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12741 · Cited by 48
Self-citationAlkallas, R., Lajoie, M., Moldoveanu, D., Hoang, K. V., Lefrançois, P., Lingrand, M., Ahanfeshar-Adams, M., Watters, K. A., Spatz, A., Zippin, J. H., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0077-8 · Cited by 43
Wilmott, J. S., Colebatch, A. J., Kakavand, H., Shang, P., Carlino, M. S., Thompson, J. F., Long, G. V., Scolyer, R. A., & Hersey, P. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.34 · Cited by 42
Lactylation of LSD1 is an acquired epigenetic vulnerability of BRAFi/MEKi-resistant melanoma
Li, A., Gong, Z., Long, Y., Li, Y., Liu, C., Xiao, L., Li, Q., He, X., Lu, H., Wu, K., et al. (2025) · Developmental Cell · doi:10.1016/j.devcel.2025.02.016 · Cited by 46
Motzik, A., Eden, A., Erlich, T. H., Wang, J., Kim, B.-G., Han, J. M., Kim, J. H., Nechushtan, H., Guo, M., Razin, E., et al. (2017) · Oncogene · doi:10.1038/onc.2017.81 · Cited by 42
Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia
Cremer, A., Ellegast, J. M., Alexe, G., Frank, E. S., Ross, L. S., Chu, S. H., Pikman, Y., Robichaud, A. L., Goodale, A. B., Häupl, B., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0209 · Cited by 42
Self-citationGorantla, V. C., & Kirkwood, J. M. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2014.02.010 · Cited by 44
Mapping the Pathways of Resistance to Targeted Therapies
Wood, K. C. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1248 · Cited by 41
Liu, Y. L., Lai, F., Wilmott, J. S., Yan, X. G., Liu, X. Y., Luan, Q., Guo, S. T., Jiang, C. C., Tseng, H.-Y., Scolyer, R. A., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2616 · Cited by 40
Involvement of androgen receptor and glucose-regulated protein 78 kDa in human hepatocarcinogenesis
Jiang, X., Kanda, T., Nakamoto, S., Miyamura, T., Wu, S., & Yokosuka, O. (2014) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.02.017 · Cited by 40
Deciphering the Role of Oncogenic MITFE318K in Senescence Delay and Melanoma Progression
Bonet, C., Luciani, F., Ottavi, J., Leclerc, J., Jouenne, F.-M., Boncompagni, M., Bille, K., Hofman, V., Bossis, G., Donatis, G. M. D., et al. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw340 · Cited by 48
Resistance to Raf inhibition in cancer
Haarberg, H. E., & Smalley, K. S. M. (2014) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2013.12.004 · Cited by 40
The role of phenotypic plasticity in the escape of cancer cells from targeted therapy
Emmons, M. F., Faião‐Flores, F., & Smalley, K. S. M. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.06.014 · Cited by 41
Ostojić, J., Yoon, Y.-S., Sonntag, T., Nguyen, B., Vaughan, J. M., Shokhirev, M. N., & Montminy, M. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109136 · Cited by 40
Oncogenic Signaling Adaptor Proteins
Luo, L. Y., & Hahn, W. C. (2015) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2015.09.001 · Cited by 39
Pathways from senescence to melanoma: focus on MITF sumoylation
Leclerc, J., Ballotti, R., & Bertolotto, C. (2017) · Oncogene · doi:10.1038/onc.2017.292 · Cited by 43
Li, S., Giardina, D., & Siegal, M. L. (2018) · PLoS Genetics · doi:10.1371/journal.pgen.1007744 · Cited by 39
Somatic Hypermutation of the YAP Oncogene in a Human Cutaneous Melanoma
Zhang, X., Tang, J., Vergara, I. A., Zhang, Y., Szeto, P., Yang, L., Mintoff, C., Colebatch, A. J., McIntosh, L., Mitchell, K. A., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0407 · Cited by 40
PDE4D promotes FAK-mediated cell invasion in BRAF-mutated melanoma
Delyon, J., Servy, A., Laugier, F., André, J., Ortonne, N., Battistella, M., Mourah, S., Bensussan, A., Lebbé, C., & Dumaz, N. (2017) · Oncogene · doi:10.1038/onc.2016.469 · Cited by 41
Kunz, M., & Hölzel, M. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9657-1 · Cited by 38
Fujita, N., Mizuarai, S., Murakami, K., & Nakai, K. (2018) · Scientific Reports · doi:10.1038/s41598-018-28066-w · Cited by 37
Epigenetic Mechanisms of Escape from BRAF Oncogene Dependency
Khaliq, M., & Fallahi‐Sichani, M. (2019) · Cancers · doi:10.3390/cancers11101480 · Cited by 39
Almahariq, M. F., Mei, F. C., & Cheng, X. (2015) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv115 · Cited by 36
Application of CRISPR genetic screens to investigate neurological diseases
So, R. W. L., Chung, S., Lau, H. H. C., Watts, J. J., Gaudette, E. V., Al‐Azzawi, Z. A. M., Bishay, J., Lin, L. T., Joung, J., Wang, X., et al. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0343-3 · Cited by 37
Genetic and Epigenetic Modulation of Drug Resistance in Cancer: Challenges and Opportunities
Shah, K., & Rawal, R. (2020) · Current Drug Metabolism · doi:10.2174/1389200221666200103111539 · Cited by 36
Metabolic Signaling Cascades Prompted by Glutaminolysis in Cancer
Shah, R., & Chen, S. (2020) · Cancers · doi:10.3390/cancers12092624 · Cited by 36
Transcriptional regulators and alterations that drive melanoma initiation and progression
Gupta, R., Janoštiak, R., & Wajapeyee, N. (2020) · Oncogene · doi:10.1038/s41388-020-01490-x · Cited by 36
Zhou, B., Ritt, D. A., Morrison, D. K., Der, C. J., & Cox, A. D. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.712885 · Cited by 36
García-Fernández, M., Karras, P., Checinska, A., Cañón, E., Calvo, G. T., Gómez-López, G., Cifdaloz, M., Colmenar, A., Espinosa-Hevia, L., Olmeda, D., et al. (2016) · Autophagy · doi:10.1080/15548627.2016.1199301 · Cited by 35
High-Throughput Silencing Using the CRISPR-Cas9 System: A Review of the Benefits and Challenges
Wade, M. R. (2015) · SLAS DISCOVERY · doi:10.1177/1087057115587916 · Cited by 39
BRN2 expression increases anoikis resistance in melanoma
Pierce, C. J., Simmons, J. L., Broit, N., Karunarathne, D. S., Ng, M. F., & Boyle, G. M. (2020) · Oncogenesis · doi:10.1038/s41389-020-00247-1 · Cited by 35
Genome-guided discovery of cancer therapeutic targets
Konda, P., Garinet, S., Allen, E. M. V., & Viswanathan, S. R. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112978 · Cited by 36
D’Amato, L., Dell’Aversana, C., Conte, M., Ciotta, A., Scisciola, L., Carissimo, A., Nebbioso, A., & Altucci, L. (2014) · Epigenetics · doi:10.4161/15592294.2014.988035 · Cited by 34
pH‐controlled histone acetylation amplifies melanocyte differentiation downstream of MITF
Raja, D. A., Gotherwal, V., Burse, S. A., Subramaniam, Y. J., Sultan, F., Vats, A., Gautam, H., Sharma, B., Sharma, S., Singh, A. K., et al. (2019) · EMBO Reports · doi:10.15252/embr.201948333 · Cited by 34
Metadata
- Authors
- Johannessen, C. M., Johnson, L. A., Piccioni, F., Townes, A., Frederick, D. T., Donahue, M. K., Narayan, R., Flaherty, K. T., Wargo, J. A., Root, D. E., & Garraway, L. A.
- Affiliations
- Broad Institute (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Garraway, Levi A.
- ORCID
- Venue
- Nature
- Published
- 2013-11-03
- Volume
- 504
- Issue
- 7478
- Pages
- 138-142
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4098832
- OpenAlex
- W2159220884
- Cited by
- 452
- References
- 28
- Citations by year
- 2026: 8 · 2025: 15 · 2024: 19 · 2023: 22 · 2022: 27 · 2021: 32 · 2020: 49 · 2019: 45 · 2018: 36 · 2017: 57 · 2016: 48 · 2015: 41 · 2014: 47 · 2013: 4
- FWCI
- 20.92
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health (DP2OD002750)
- National Human Genome Research Institute (U54HG006093, U01HG006492)
- National Cancer Institute (P50-CA-93683, R33CA155554, P50CA093683, P01CA163222)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- BRAF V600E mutation, cAMP signaling, CREB, MITF, melanocyte lineage, RAF inhibitors, MEK inhibitors, histone deacetylase inhibitors, G protein-coupled receptors, adenylate cyclase, c-fos, drug resistance mechanisms, therapeutic target
- MeSH terms
- Cyclic AMP, Antineoplastic Agents, Humans, Melanocytes, Melanoma, Transcription Factors, Signal Transduction, Gene Expression Regulation, Neoplastic, Drug Resistance, Neoplasm, Cell Lineage, Mitogen-Activated Protein Kinases, Cell Line, Tumor, Protein Kinase Inhibitors, CREB-Binding Protein, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
